低聚异麦芽糖生产工艺研究

摘要：低聚异麦芽糖是一种功能性低聚糖,因其具有多种独特生理功能,被广泛地应用于食品、医药、饲料等领域,市场前景十分广阔,但是目前低聚异麦芽糖生产工艺中存在许多不足之处。本文首先介绍了低聚异麦芽糖的性质和生理功能,其次阐述了低聚异麦芽糖的生产工艺,并对如何构建和利用基因工程菌生产低聚异麦芽糖提出展望。     

解脂耶氏酵母表面展示β-淀粉酶与α-葡萄糖转苷酶及一步法由淀粉合成低聚异麦芽糖

低聚异麦芽糖(IMO)所具有的良好理化性质和生理功能,使得其在食品、医药、饲料、化妆品等领域得到广泛应用。但目前工业上采用多酶协同法由淀粉合成低聚异麦芽糖,步骤繁琐、成本较高。因此开发出更加经济简便的方法生产低聚异麦芽糖具有重要的应用价值。通过将β-淀粉酶(βa)和耐热α-葡萄糖转苷酶(GT)以不同的方式进行融合,并利用表面展示系统固定在食品安全微生物解脂耶氏酵母细胞表面,实现自我表达与固定。筛选得到高产菌株Yβa-GT29。大量培养获得细胞,转化液化的淀粉可实现一步法合成IMO,50℃转化20h即可得到纯度为75.3%的低聚异麦芽糖,方便了低聚异麦芽糖的生产。     

低聚异麦芽糖对模拟失重大鼠肠道益生菌以及钙代谢和骨矿盐密度影响的初步研究

目的：研究低聚异麦芽糖对模拟失重大鼠肠道益生菌的影响以及与骨钙代谢变化的关系。方法：30只雄性SD大鼠随机分为3组（每组10只）FC组;普通对照组（饲喂普通饲料）;SC组,模拟失重对照组（饲喂普通饲料）;SS组,模拟失重低聚异麦芽糖组（饲喂普通饲料 低聚异麦芽糖）,实验期21d。结果：SC组大鼠肠道益生菌（主要是双歧杆菌和乳杆菌）数量、饲料钙的表观吸收率、股骨骨密度（BMD）,骨钙含量以及骨钙素（BGP）的水平显著低于FC组,而血钙水平明显高于FC组;SS组大鼠肠道益生菌数量,饲料钙的表观吸收率,骨密度,骨钙含量以及骨钙素水平较SC组高,血钙水平显著低于SC组。结论：低聚异麦芽糖可以促进模拟失重大鼠肠道益生菌的增殖,减少股骨骨质的丢失,提高股骨BMD,增加骨形成,对骨代谢产生一定的有益影响。     

藤黄微球菌海藻糖生物合成基因的克隆与鉴定

首次从一株能利用淀粉产生海藻糖的藤黄微球菌中克隆了海藻糖生物合成基因。采用PCR方法结合非随机鸟枪法得到藤黄微球菌中低聚麦芽糖苷基海藻糖合成酶(MTSase)基因(MtreY)的全序列及低聚麦芽糖苷基海藻糖水解酶(MTHase)基因(MtreZ)的部分序列,其中MtreY共有2,370个碱基,编码789个氨基酸,表达产物分子量为86·7kD。同源性分析表明,与已报道的MTSase和α-淀粉酶家族成员具有相同的保守模体。将MtreY基因在大肠杆菌JM83中表达,证明表达产物具有预期的酶活性。     

高产α-转移葡萄糖苷酶菌株的诱变选育研究

α-转移葡萄糖苷酶是生产低聚异麦芽糖的关键酶。该文成功筛选了2株产α-转移葡萄糖苷酶菌株。在此基础上,进行了菌株的诱变选育和遗传稳定性试验,确定2株产酶酶活较高的突变株,有望将来应用于低聚异麦芽糖的生产中。     

低聚壳聚糖美拉德衍生物抑菌性能研究

本文研究了基于与葡萄糖、麦芽糖和木糖进行美拉德反应的低聚壳聚糖衍生物的抑菌性.测定低聚壳聚糖及其衍生物对大肠杆菌和金黄色葡萄球菌的抑制效果.结果显示:壳聚糖及其衍生物对金黄色葡萄球菌的抑制作用强于对大肠杆菌的抑制作用,且随着浓度增加,对两种菌的抑菌效果增强.大多数壳聚糖衍生物的抑菌效果优于壳聚糖本身,其中CG 1∶1 8 h(低聚壳聚糖的氨基与葡萄糖的羰基的物质量比为1∶1,反应8h)的抑菌效果最好,CM 1∶3 8 h(低聚壳聚糖的氨基与麦芽糖的羰基的物质量比为1∶3,反应8 h)抑菌性最差,这可能与参加反应的还原糖种类、反应物比例以及反应时间相关.     

功能性低聚糖生产工艺的研究现状

功能性低聚糖（functional oligosaccharides）是由2—10个单糖通过糖苷键连接形成直链或支链的一类寡糖,具有低热量、抗龋齿、抗肿瘤、防治糖尿病、防止腹泻和便秘等生理作用。因具有糖类某些共同特性,可作为甜食配料,但人体肠道内不具备分解消化功能性低聚糖的酶系统,所以不被人体胃酸、胃酶降解,不在小肠吸收,直接进入大肠内为双歧杆菌所利用,是一类优良的双歧杆菌增殖因子,故又名双歧因子。功能性低聚糖包括水苏糖、棉子糖、低聚果糖、低聚木糖、低聚半乳糖、大豆低聚糖和低聚异麦芽糖等。近年来,国外上市品种有10多种,生产批量较大,我国自1996年开始才有批量生产,主要以低聚异麦芽糖、低聚果糖和大豆低聚糖为主。本文综述了不同种类的功能性低聚糖及生产工艺的现状。     

藤茶保健含片的研制

以藤茶浓缩汁、麦芽糖醇、山梨糖醇和低聚异麦芽糖为主要原料,经混合、造粒、干燥、压片等工序,制成了低热量、具有保健功能的藤茶含片.     

我国功能性低聚糖产业发展现状及发展趋势分析

功能性低聚糖由于具有独特功效,目前作为益生元、食品添加剂、饲料添加剂广泛应用于食品和饲料行业。近年来我国以低聚木糖、低聚果糖、低聚异麦芽糖为代表的功能性低聚糖发展迅猛,市场潜力巨大,但也存在品种单一、生产技术落后、产业化程度不高等问题。通过对我国功能性低聚糖产业整体发展现状,以及主要功能性低聚糖的产业化现状的分析,为相关研究者提供参考。     

一种新型淀粉酶的鉴定及其产酶菌株的筛选*

对筛选到的菌株ZX99产生的一种新型淀粉酶 (异麦芽低聚糖酶 )进行了分析鉴定。ZX99菌株能产生一种胞外淀粉酶 ,该酶能催化淀粉的降解产生异麦芽低聚糖。对原产酶菌株ZX99多次进行紫外线照射诱变后 ,获得了优良、稳定的变异菌株BS3.232 ,其产酶水平为原株的160 %。产物薄层层析证明 ,该酶能催化淀粉的降解 ,产生异麦芽糖、潘糖、异麦芽三糖和异麦芽四糖等低聚糖 ,但对普鲁兰基本不起作用 ,由此证明它是一种不同于新型普鲁兰酶 (neopullulanase)和传统淀粉酶 (amylase)的一种新型     

Isomaltose formation by free and immobilized dextransucrase

The acceptor reaction of dextransucrase from Leuconostoc mesenteroides NRRL-B512F with glucose as acceptor is of technical interest for isomaltooligosaccharide (IMOs) synthesis. Different experimental conditions were investigated for free and immobilized enzyme. The data for oligosaccharide formation up to a degree of polymerization 4 were correlated with a model developed earlier, and optimal reaction conditions for immobilized dextransucrase design and application were identified for later continuous application. Furthermore, stability was investigated for free and immobilized enzyme including stabilization by sugars.     

Isomaltose formation by free and immobilized dextransucrase

The acceptor reaction of dextransucrase from Leuconostoc mesenteroides NRRL-B512F with glucose as acceptor is of technical interest for isomaltooligosaccharide (IMOs) synthesis. Different experimental conditions were investigated for free and immobilized enzyme. The data for oligosaccharide formation up to a degree of polymerization 4 were correlated with a model developed earlier, and optimal reaction conditions for immobilized dextransucrase design and application were identified for later continuous application. Furthermore, stability was investigated for free and immobilized enzyme including stabilization by sugars.     

Suppression of Molecular Inflammatory Pathways by Toll-Like Receptor 7, 8, and 9 Antagonists in a Model of IL-23-Induced Skin Inflammation

Psoriasis is a complex inflammatory disease resulting from the activation of T helper (Th) 1 and Th17 cells. Recent evidence suggests that abnormal activation of Toll-like receptors (TLRs) 7, 8 and 9 contributes to the initiation and maintenance of psoriasis. We have evaluated the effects of TLR antagonists on the gene expression profile in an IL-23-induced skin inflammation model in mice. Psoriasis-like skin lesions were induced in C57BL/6 mice by intradermal injection of IL-23 in the dorsum. Two TLR antagonists were compared: IMO-3100, an antagonist of TLRs 7 and 9, and IMO-8400, an antagonist of TLRs 7, 8 and 9, both of which previously have been shown to reduce epidermal hyperplasia in this model. Skin gene expression profiles of IL-23-induced inflammation were compared with or without TLR antagonist treatment. IL-23 injection resulted in alteration of 5100 gene probes (fold change ≥ 2, FDR < 0.05) including IL-17 pathways that are up-regulated in psoriasis vulgaris. Targeting TLRs 7, 8 and 9 with IMO-8400 resulted in modulation of more than 2300 mRNAs while targeting TLRs 7 and 9 with IMO-3100 resulted in modulation of more than 1900 mRNAs. Both agents strongly decreased IL-17A expression (>12-fold reduction), normalized IL-17 induced genes such as beta-defensin and CXCL1, and normalized aberrant expression of keratin 16 (indicating epidermal hyperplasia). These results suggest that IL-23-driven inflammation in mouse skin may be dependent on signaling mediated by TLRs 7, 8, and 9 and that these receptors represent novel therapeutic targets in psoriasis vulgaris and other diseases with similar pathophysiology.     

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib,and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

Background

IMO-2055 is a Toll-like receptor 9 (TLR9) agonist that potentially enhances the efficacy of antitumor agents through immune stimulation. The objective of this phase Ib dose-escalation trial (3 + 3 design) was to determine the recommended phase II dose (RP2D) of IMO-2055 when combined with erlotinib and bevacizumab in patients with advanced non-small cell lung cancer (NSCLC).

Methods

Patients with stage 3/4 NSCLC and progressive disease (PD) following chemotherapy received IMO-2055 0.08, 0.16, 0.32, or 0.48 mg/kg once weekly plus erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks. Patients could receive treatment until PD or unacceptable toxicity.

Results

Thirty-six patients were enrolled; 35 received at least one treatment dose. Two dose-limiting toxicities were observed across the dose range (Grade 3 dehydration and fatigue) with neither suggestive of a consistent toxicity pattern. IMO-2055 0.32 mg/kg was adopted as RP2D based on clinical and pharmacodynamic data. The most common treatment-emergent adverse events (TEAEs) were diarrhea (74 %), nausea (51 %), fatigue (51 %), rash (51 %), and injection-site reactions (49 %). Four patients experienced serious TEAEs considered to be study drug related. Five patients died, all due to PD. High-grade neutropenia and electrolyte disturbances previously reported with TLR9 agonists combined with platinum-based therapy were not observed in this study. Five of 33 patients evaluable for response (15 %) achieved partial response; another 20 (61 %) had stable disease, including 13 with stable disease ≥4 months.

Conclusions

IMO-2055 demonstrated good tolerability and possible antitumor activity in combination with erlotinib and bevacizumab in heavily pretreated patients with advanced NSCLC.     

吸附树脂分离纯化高麦芽糖浆的研究

本文提出并研究了吸附树脂分离纯化提高麦芽糖浆的新工艺,选出了较适合的吸附树脂进行了交换柱吸附分离提纯及其再生方法试验。结果表明,ＷＩ树脂对超高麦芽糖浆中的低聚糖具有较好的吸附分离效果。在交换柱中进行吸附分离试验时,单批处理量为０．６７ｍｌ／ｇ树脂时,ＷＩ吸附低聚为９１．０％以上。     

利用菌丝渣和中和滤液生产蛋白饲料

选育出了新的菌种K6,并以K6为菌源 ,利用柠檬酸生产过程中的主要副产物菌渣和中和滤液 (废糖水 )为原料生产蛋白饲料 ,经处理后的废糖水完全达到了治污排放标准。     

Effects of Dietary Supplementation of Probiotic Mix and Prebiotic on Growth Performance,Cecal Microbiota Composition,and Protection Against Escherichia coli O78 in Broiler Chickens

Probiotics and Antimicrobial Proteins - The current study conducted to investigate the effects of a multi-strain commercial probiotic mix and prebiotic (isomaltooligosaccharide, IMO) on broiler...     

Engineered dextranase from Streptococcus mutans enhances the production of longer isomaltooligosaccharides

Herein, we investigated enzymatic properties and reaction specificities of Streptococcus mutans dextranase, which hydrolyzes α-(1→6)-glucosidic linkages in dextran to produce isomaltooligosaccharides. Reaction specificities of wild-type dextranase and its mutant derivatives were examined using dextran and a series of enzymatically prepared p-nitrophenyl α-isomaltooligosaccharides. In experiments with 4-mg·mL^?1 dextran, isomaltooligosaccharides with degrees of polymerization (DP) of 3 and 4 were present at the beginning of the reaction, and glucose and isomaltose were produced by the end of the reaction. Increased concentrations of the substrate dextran (40 mg·mL^?1) yielded isomaltooligosaccharides with higher DP, and the mutations T558H, W279A/T563N, and W279F/T563N at the ?3 and ?4 subsites affected hydrolytic activities of the enzyme, likely reflecting decreases in substrate affinity at the ?4 subsite. In particular, T558H increased the proportion of isomaltooligosaccharide with DP of 5 in hydrolysates following reactions with 4-mg·mL^?1 dextran.Abbreviations CI: cycloisomaltooligosaccharide; CITase: CI glucanotransferase; CITase-Bc: CITase from Bacillus circulans T-3040; DP: degree of polymerization of glucose unit; GH: glycoside hydrolase family; GTF: glucansucrase; HPAEC-PAD: high performance anion-exchange chromatography-pulsed amperometric detection; IG: isomaltooligosaccharide; IGn: IG with DP of n (n, 2?5); PNP: p-nitrophenol; PNP-Glc: p-nitrophenyl α-glucoside; PNP-IG: p-nitrophenyl isomaltooligosaccharide; PNP-IGn: PNP-IG with DP of n (n, 2?6); SmDex: dextranase from Streptococcus mutans; SmDexTM: S. mutans ATCC25175 SmDex bearing Gln100?Ile732     

Isolation of new ethanol-tolerant yeasts for fuel ethanol production from sucrose

Summary New ethanol-tolerant yeast strains were isolated from crude recycled yeasts used for fuel ethanol production in the 1983 sugar cane crop. The ethanol-tolerant isolates were able to produce and tolerate ethanol above 20% (v/v) in the fermentation of sugar cane syrup.